Home › Compare › UCLQF vs ABBV
UCLQF yields 0.87% · ABBV yields 3.06%● Live data
📍 UCLQF pulled ahead of the other in Year 6
Combined, UCLQF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UCLQF + ABBV for your $10,000?
UltraTech Cement Limited, together with its subsidiaries, manufactures and sells cement and cement related products in India. It offers ordinary Portland cement, Portland blast furnace slag cement, Portland Pozzolana cement, white cement, and white cement-based products; and ready-mix concrete. The company also provides Tile Adhesive polymer under TILEFIXO, FLEX, HIFLEX,MYKROFILL, Seal & Dry water proofing products for kitchen balconies, chajjas, slope roofs, bathrooms, canal linings, swimming pools, and water tanks; Power Grout, an industrial grout for machine foundation, precast elements, and safety vaults; Readi Plast and Super Stucco, a plastering agent for internal and external walls; as well as liquid system for mortar and concrete modifier, repair mortars and concrete under the name of Basekrete and Microkrete. In addition, the company offers bed jointing material for AAC block, Fly Ash Bricks, and concrete blocks, and light weight block for masonry construction, and flooring screeds. Further, the company offers construction products for home builders; and value-added services that include technical advice during concreting, vaastu consultancy, various training programs, and other related services. UltraTech Cement Limited exports its products to the United Arab Emirates, Bahrain, and Sri Lanka. The company was incorporated in 2000 and is based in Mumbai, India. UltraTech Cement Limited operates as a subsidiary of Grasim Industries Limited.
Full UCLQF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.